Hiroaki Sasaki

Hiroaki Sasaki

Auto-generated profile, based on publicly available information

Hiroaki Sasaki

Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SMShoji Miki
Shoji Miki
HSHiroaki Sasaki
Hiroaki Sasaki
HHHiroshi Horiuchi
Hiroshi Horiuchi
NMNobuyuki Miyata
Nobuyuki Miyata
YYYukihiro Yoshimura
Yukihiro Yoshimura
NTNatsuo Tachikawa
Natsuo Tachikawa
Background: This study aimed to clarify how SARS-CoV-2 RNAemia is related to COVID-19 critical condition development and mortality in comparison with other predictive markers and scoring systems. Methods: This is a retrospective cohort study conducted at Yokohama Municipal Citizen’s Hospital and National Institute of Infectious Diseases. We recruited adult patients with COVID-19 admitted between March 2020 and January 2021. We compared RNAemia with clinical status on admission including scoring systems such as the 4C Mortality, CURB-65, and A-DROP, as well as the Ct value of the nasopharyngeal PCR, in predicting COVID-19 mortality and critical condition development. Results: Of the 92 recruited patients (median age, 58; interquartile range, 45–71 years), 14 (14.9%) had RNAemia. These patients had an older age (median, 68 years vs. 55.5 years; p = 0.011), higher values of lactated dehydrogenase (median, 381 U/L vs. 256.5 U/L, p < 0.001), C-reactive protein (median, 10.9 mg/dL vs. 3.8 mg/dL; p < 0.001), D-dimer (median, 2.07 μg/mL vs. 1.28 μg/mL; p = 0.015), lower values of lymphocyte (median, 802/μL vs. 1007/μL, p = 0.025) and Ct of the nasopharyngeal PCR assay (median, 20.59 vs. 25.54; p = 0.021) than those without RNAemia. Univariate analysis showed RNAemia was associated with mortality (odds ratio [OR], 18.75; 95% confidence interval [CI], 3.92–89.76; area under the receiver operating characteristic curve [AUC], 0.7851; p = 0.002) and critical condition (OR, 72.00; 95% CI, 12.98–399.29; AUC, 0.8198; p < 0.001). Plus, multivariate analysis also revealed the association of RNAemia with critical condition (adjusted OR, 125.71; 95% CI, 11.47–1377.32; p < 0.001). Conclusion: On-admission SARS-CoV-2 RNAemia is a potent predictive marker of COVID-19 critical condition and mortality. The adjusted OR for critical condition was as high as 125.71.

30 April 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
YYYukihiro Yoshimura
Yukihiro Yoshimura
HSHiroaki Sasaki
Hiroaki Sasaki
NMNobuyuki Miyata
Nobuyuki Miyata
KMKazuhito Miyazaki
Kazuhito Miyazaki
KOKoji Okudela
Koji Okudela
NTNatsuo Tachikawa
Natsuo Tachikawa
We report the first case with COVID-19-like acute respiratory distress syndrome after mRNA-1273 SARS-CoV-2 vaccination. An 88-year-old woman developed dyspnea several hours after vaccination with the second dose of mRNA-1273. She was hospitalized on day nine due to worsening dyspnea. Chest computed tomography showed bilateral ground-glass opacities and consolidations, mainly in the peripheral lung areas. Repeat polymerase chain reaction tests for SARS-CoV-2 were negative, although the serum level of antibodies against spike protein was extremely elevated. Her condition did not improve with high-dose corticosteroids and high-flow nasal cannula oxygen therapy; she died on day 18. Autopsy findings revealed very early-phase diffuse alveolar damage in the whole lung without other lung diseases. The clinical and pathological findings suggested vaccine-induced acute respiratory distress syndrome. Serological and pathological tests might be useful to differentiate the disease from COVID-19.

4 May 2022 in Heliyon
Verified
Journal Article
Open access
SHSatoshi Hara
Satoshi Hara
TSTama Sanatani
Tama Sanatani
NTNatsuo Tachikawa
Natsuo Tachikawa
YYYukihiro Yoshimura
Yukihiro Yoshimura
NMNobuyuki Miyata
Nobuyuki Miyata
HIHiroshi Ichinose
Hiroshi Ichinose
Neopterin (NP) is a biomarker for activated cellular immunity and is elevated in diseases including viral and bacterial infections, autoimmune diseases, and cancer. However, the clinical assessment of neopterin has not been used for these disorders because the physiological significance of measuring NP is obscure. It would be important to compare the NP profiles with those of other inflammation markers especially in relatively early phase of patients to reveal the significance of NP measurements in pathological states. Plasma NP, biopterin, CRP, and IL-6 levels were measured in 46 patients with Coronavirus Disease 2019 (COVID-19) and 23 patients with non-COVID-19 disorders. The correlations between these markers were analyzed in the COVID-19 and non-COVID-19 patients independently. The NP levels were significantly higher in the COVID-19 patients than in the non-COVID-19 patients, while biopterin, CRP and IL-6 were not changed significantly. The NP levels were found to show a weak negative correlation against the days after onset in the COVID-19 patients (rs = –0.348, p = 0.0192), suggesting that the elevation of NP would be an early event of viral infection. Correlations between NP and CRP, or between NP and IL-6 in COVID-19 patients were weaker than that between CRP and IL-6. The elevation of NP levels was supposed to be distinct from those of CRP and IL-6 in relatively early and mild COVID-19 patients. Our data suggest that NP is produced at the early phase of infection by different signaling pathways and/or cells from those of CRP and IL-6. Further study on the signaling pathway to induce NP is expected.

21 September 2022 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
MNMasayuki Nishiyama
Masayuki Nishiyama
YIYosuke Inoue
Yosuke Inoue
HSHiroaki Sasaki
Hiroaki Sasaki
YSYoshimasa Seike
Yoshimasa Seike
TATatsuo Aoki
Tatsuo Aoki
TSTaichi Sakaguchi
Taichi Sakaguchi

18 February 2022 in Infection
Verified
Journal Article
Closed access
PDF file
HSHiroaki Sasaki
Hiroaki Sasaki
NMNobuyuki Miyata
Nobuyuki Miyata
YYYukihiro Yoshimura
Yukihiro Yoshimura
NTNatsuo Tachikawa
Natsuo Tachikawa

23 October 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
MKMasaki Kakimoto
Masaki Kakimoto
TNToshihito Nomura
Toshihito Nomura
TNTanuza Nazmul
Tanuza Nazmul
AYAkima Yamamoto
Akima Yamamoto
HSHiroaki Sasaki
Hiroaki Sasaki
TSTakemasa Sakaguchi
Takemasa Sakaguchi
The terrestrial stems of Ephedra (Ephedra spp.; including Ephedra sinica Stapf and Ephedra przewalskii Stapf) extracts are used in traditional medicines in East Asia. In Japan, the Kampo formula containing E. sinica extract is prescribed for the treatment of the common cold, influenza virus infections, and mild symptoms of coronavirus disease 2019 (COVID-19). Although ephedrine alkaloids in E. sinica exert antitussive effects, they may have side effects associated with the sympathetic nervous system. E. przewalskii extract, a drug used in traditional Uyghur and Mongolian medicine, is considered to be free of ephedrine alkaloids and is a promising candidate for the treatment of infectious diseases. However, its use is currently limited because evidence of its antiviral efficacy remains inconclusive. We compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) effects of E. przewalskii and E. sinica extracts in vitro. Additionally, we examined the differences in their antiviral effects against different SARS-CoV-2 strains. VeroE6/TMPRSS2 cells were infected with SARS-CoV-2 (Conventional, Delta, and Omicron strains-BA.1, BA.2, BA.4, and BA.5), and lysates prepared from each herbal extract were added. The infectious titer was determined using the 50% tissue culture infectious dose (TCID50) method; in turn, the half-maximal inhibitory concentration (IC50) was calculated for each extract to compare the antiviral efficacy of E. sinica and E. przewalskii extracts. Further, the extracts were compared with remdesivir for their antiviral efficacy against the conventional viral strain. To verify the effect of the inactivation of virus particles, these extracts were added to each SARS-CoV-2 strain, and the infectious titers were determined using the TCID50 method. The antiviral efficacy (i.e., IC50) of the E. przewalskii extract against each SARS-CoV-2 strain was 2.7-10.8-fold greater than that of the E. sinica extract. The antiviral efficacy of the E. przewalskii extract against conventional viral strains was compared with that of remdesivir, which was 1/27.6 of remdesivir's efficacy. The E. sinica extract showed minimal inactivation of virus particles of each strain, whereas the E. przewalskii extract resulted in substantial viral inactivation. The E. przewalskii extract showed higher antiviral activity against SARS-CoV-2 than the E. sinica extract. Overall, our study suggests that E. przewalskii extract can be used for the treatment of viral infections, including COVID-19.